Sjögren's disease & overlap diseases
Salivary cystatin D is a candidate non-invasive biomarker for primary Sjögren's syndrome diagnosis and salivary gland injury
Authors' conclusion
Salivary cystatin D emerged as a promising biomarker for pSS diagnosis and was correlated with salivary gland dysfunction.
Study context
- Population
- Patients with primary Sjögren's syndrome (pSS), patients with head and neck cancer after radiotherapy, and healthy controls
- Participants
- 73 / 23 / 58
- Comparison
- Salivary cystatin D in pSS vs patients with head and neck cancer after radiotherapy vs healthy controls
- pSSn = 73
- HNCRn = 23reference
- Healthy controls (HC)n = 58reference
- Outcome
- Diagnostic value of salivary cystatin D (enzyme-linked immunosorbent assay (ELISA)) for pSS by ROC analysis
Methodological detailscase-control
- Case-control
Performance
As reported in the abstract
Diagnostic performance of salivary cystatin D for pSS (ROC)
| Test or model | AUC | Sensitivity | Specificity |
|---|---|---|---|
| Salivary cystatin D | 0.713 (95% CI: 0.632, 0.749, p<0.001) | 51.9% | 83.6% |
Salivary cystatin D
AUC0.713 (95% CI: 0.632, 0.749, p<0.001)
Sensitivity51.9%
Specificity83.6%
Further findings
| Outcome | P value |
|---|---|
| Salivary cystatin D levelspSS vs HNCR · significantly reduced in pSS | P < 0.001 |
| Salivary cystatin D levelspSS vs HC · significantly reduced in pSS | P < 0.001 |
Correlations of salivary cystatin D in pSS
- Positively correlated with USFR and SSFR; negatively correlated with serum IL-6, IgE and peripheral blood CD4+ T cell counts
Salivary cystatin D by gland US score in pSS
- Significantly reduced in pSS patients with parotid or submandibular gland US scores ≥ 2
Diagnostic accuracy in anti-SSA negative pSS
- Cystatin D improved the accuracy of pSS diagnosis, particularly in patients with negative anti-SSA
Original publication
Salivary cystatin D is a candidate non-invasive biomarker for primary Sjögren's syndrome diagnosis and salivary gland injury. Clin Exp Rheumatol. Published 27 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →